A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results